A multi-center clinical trial for the treatment of those experiencing prolonged coronavirus disease 2019 (COVID-19) Symptoms (Long Haulers Syndrome)
Latest Information Update: 02 Jun 2021
At a glance
- Drugs Ischaemia-tolerant mesenchymal stem cells (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 02 Jun 2021 New trial record
- 24 May 2021 According to a Stemedica Cell Technologies media release, trial initiation anticipated late in 2021 by Pulthera.